Compound having affinity substance to soluble protein, cleavable portion and reactive group, or salt thereof
The present invention provides a technique enabling modification of a soluble protein and in particular regioselective modification of a soluble protein. More specifically, the present invention provides a compound having an affinity substance to a soluble protein, a cleavable portion, and a reactive group represented by the following Formula (I): A-L-B-R (I) wherein A is an affinity substance to a soluble protein; L is a cleavable linker which is a divalent group comprising a cleavable portion; B is (a) a divalent group comprising a bioorthogonal functional group or (b) a divalent group comprising no bioorthogonal functional group; and R is a reactive group to the soluble protein; or a salt thereof.
1. An antibody or salt thereof regioselectively having at least one functional substance,
wherein the antibody comprises one or more lysine residues in a target region consisting of 1 to 50 continuous amino acid residues present in CH2 domain, and five or more lysine residues in a non-target region other than the target region, and
the at least one functional substance binds to the one or more lysine residues in the target region with 30% or more regioselectivity through a linker comprising no peptide portion,
wherein the antibody does not comprise an affinity substance to the antibody,
wherein the at least one functional substance is a drug, a labelling substance, or a stabilizer.
2. An antibody or a salt thereof regioselectively having at least one bioorthogonal functional group,
wherein the antibody comprises one or more lysine residues in a target region consisting of 1 to 50 continuous amino acid residues present in CH2 domain Fe-region, and five or more lysine residues in a non-target region other than the target region, and
the at least one bioorthogonal functional group binds to the one or more lysine residues in the target region with 30% or more regioselectivity through a linker comprising no peptide portion,
wherein the antibody does not comprise an affinity substance to the antibody,
wherein the at least one bioorthogonal functional group is one or more residues selected from the group consisting of an azide residue, an aldehyde residue, a thiol residue, an alkene residue, an alkyne residue, a halogen residue, a tetrazine residue, a nitron residue, a hydroxyamine residue, a nitrile residue, a hydrazine residue, a ketone residue, a boric acid residue, a cyanobenzothiazole residue, an allyl residue, a phosphine residue, a maleimide residue, a disulfide residue, a thioester residue, an α-halocarbonyl residue, an isonitrile residue, a sydnone residue, and a selenium residue.
3. The antibody or salt thereof according to claim 1 , wherein the antibody is a monoclonal antibody.
4. The antibody or salt thereof according to claim 1 , wherein the antibody is an IgG antibody.
5. The antibody or salt thereof according to claim 1 , wherein the antibody is derived from a human.
6. The antibody or salt thereof according to claim 1 ,
wherein the antibody comprises any one Fc region selected from the group consisting of the following (A) to (C):
(A) an Fc region comprising the amino acid sequence of SEQ ID NO: 1;
(B) an Fc region comprising an amino acid sequence with one to twenty amino acid residues inserted, added, deleted, or substituted in the amino acid sequence of SEQ ID NO: 1; and
(C) an Fc region comprising an amino acid sequence having 90% or more identity to the amino acid sequence of SEQ ID NO: 1.
7. The antibody or salt thereof according to claim 1 , wherein the target region is a region consisting of one to three continuous amino acid residues.
8. The antibody or salt thereof according to claim 7 , wherein the target region is (a) a region consisting of amino acid residues at positions 246 to 248 in an human IgG Fc region according to EU numbering, (b) a region consisting of amino acid residues at positions 288 to 290 in the human IgG Fc region according to EU numbering, or (c) a region consisting of an amino acid residue at position 317 in the human IgG Fc region according to EU numbering.
9. The antibody or salt thereof according to claim 1 , wherein the regioselectivity is 90% or more.
10. The antibody or salt thereof according to claim 1 ,
wherein the antibody is a multimeric protein comprising a plurality of monomeric proteins, and
the at least one functional substance is present in positions of the one or more lysine residues in the target regions in a plurality of monomeric proteins such that the multimeric protein has a plurality of functional substances.
11. The antibody or salt thereof according to any one of claims 1,3 to 9, and 10 , wherein the antibody is an antibody comprising a plurality of heavy chains, and the functional substances are present in positions of the one or more lysine residues in the target regions in a plurality of heavy chains such that the antibody has a plurality of functional substances.
12. The antibody or salt thereof according to claim 1 , wherein the functional substance is a drug, a labelling substance, or a stabilizer.
13. The antibody or salt thereof according to claim 2 ,
wherein the antibody is a multimeric protein comprising a plurality of monomeric proteins, and
the at least one bioorthogonal functional groups are present in positions of the one or more lysine residues in the target regions in a plurality of monomeric proteins such that the multimeric protein has a plurality of bioorthogonal functional groups.
14. The antibody or salt thereof according claim 2 ,
wherein the antibody is an antibody comprising a plurality of heavy chains, and
the at least one bioorthogonal functional groups are present in positions of the one or more lysine residues in the target regions in a plurality of heavy chains such that the antibody has a plurality of bioorthogonal functional groups.